menu
    • menu
    [{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"TFS Health Science","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ TFS Health Science","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ TFS Health Science"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ CytoAgents","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ CytoAgents"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ CytoAgents","highestDevelopmentStatusID":"4","companyTruncated":"CytoAgents \/ CytoAgents"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Novotech"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Richard King Mellon Foundation"},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ National Institutes of Health"},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by CytoAgents

    Menu

    CytoAgents

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CytoAgents Receives Fourth Grant From National Institutes of Health

                            Details : The proceeds will accelerate the development of CTO1681, an investigational new drug that uses a novel approach to prevent and mitigate CRS and ICANS.

                            Product Name : CTO1681

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 01, 2025

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents Completes Phase 1B Cohort 1 for Cytokine Release Syndrome

                            Details : CTO1681 is a GPCR agonist, small molecule drug candiate, which is being evaluated for the treatment of cytokine release syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 24, 2025

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release ...

                            Details : CTO1681 cell therapy, prevents and treats Cytokine Release Syndrome by targeting the NF-kB signaling pathway via the activation of the EP4 receptor, which reduces NF-kB signaling.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 17, 2023

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

                            Details : CTO1681 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cytokine Release Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 15, 2023

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : IND Enabling

                            Sponsor : TFS Health Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncol...

                            Details : CTO1681 reduces cytokines generated during CRS induced by bispecific antibodies without causing systemic off-target effects or increasing the risk of neurotoxicity like current CRS treatments.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2023

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : IND Enabling

                            Sponsor : TFS Health Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents’ Phase 1 Trials Show “Cytokine Release Syndrome” Drug Candidate Safe

                            Details : The safety data presented in the final clinical study report supports further human clinical development of GP1681 used to treat the excessive inflammatory response triggered by many diseases and therapies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 10, 2021

                            Lead Product(s) : GP1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP1681

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents Launches Clinical Trials for GP1681, Treatment of COVID-19 Cytokine Storm

                            Details : The new clinical trial is designed to evaluate the use of GP1681 as a potential new medicine to treat the severe immune response to COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 13, 2020

                            Lead Product(s) : GP1681

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP1681

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Richard King Mellon Foundation

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CytoAgents Receives Funding to Accelerate COVID-19 Clinical Trials for Cytokine Storm Treatment From Richard K...

                            Details : The funding would accelerate the development of CytoAgents' lead drug candidate, GP1681, an investigational new drug to treat “cytokine storm” induced by COVID-19, from the Richard King Mellon Foundation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 07, 2020

                            Lead Product(s) : GP1681

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Richard King Mellon Foundation

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP1681

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $1.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm

                            Details : The Phase II SBIR grant is non-dilutive funding from the National Institute of Allergy and Infectious Diseases of the NIH and will advance the research of GP1681.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 13, 2020

                            Lead Product(s) : GP1681

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $1.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Recipient : Quotient Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

                            Details : The collaboration aims to focus on the development of GP1681 (CTO1681), which is a small molecule inhibitor of cytokine release targeting the NF-kB signaling pathway via the activation of the EP4 receptor. It is under development for treatment of cytokin...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 28, 2020

                            Lead Product(s) : GP1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Quotient Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth